Boehringer Sues Sun to Block Copies of Trijardy XR Diabetes Drug

Boehringer Ingelheim said Sun Pharma’s proposed generic version of a once-daily tablet combining three drugs for the treatment of diabetes infringes a patent for Trijardy XR.

• Boehringer is seeking a court order blocking copies until the patent has expired, and to collect cash compensation if copies are made before then, according to complaint filed Monday in federal court in Wilmington, Delaware
• The U.S. Food and Drug Administration approved Trijardy XR in late January
• Patent covers Trijardy XR’s pharmaceutical composition, complaint says, and expires in August 2028, according to supplemental filing
• Patent is part of lawsuits Boehringer filed starting in ...